Want to see TRAX full AI Analyst Report?
First Tracks Biotherapeutics Inc (TRAX) Stock Forecast & Price Target
TRAX Analyst Ratings
Strong Buy
11Buy0Hold0Sell
Based on 11 analysts giving stock ratings to First Tracks Biotherapeutics Inc in the past 3 months
TRAX Stock 12 Month Forecast
Average Price Target
$74.20▲(64.60% Upside)Based on 11 Wall Street analysts offering 12 month price targets for First Tracks Biotherapeutics Inc in the last 3 months. The average price target is $74.20 with a high forecast of $100.00 and a low forecast of $57.00. The average price target represents a 64.60% change from the last price of $45.08.
Past 12 Months12 Month ForecastDec2025Sep2026
High$100.00
Average$74.20
Low$57.00
Highest Price TargetHighest$100.00Average Price Target$74.20Lowest Price TargetLowest$57.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yasmeen Rahimi | Piper Sandler | $95 | buy | 110.74%Upside | Reiterated | 10/20/26 | ||
| David Risinger | Leerink Partners | $70→$90 | buy | 99.65%Upside | Reiterated | 10/19/26 | ||
| Derek Archila | Wells Fargo | $62→$70 | buy | 55.28%Upside | Reiterated | 10/13/26 | ||
| Etzer Darout | Barclays | $65 | buy | 44.19%Upside | Reiterated | 10/13/26 | ||
| Edward Nash | Canaccord Genuity | $50→$60 | buy | 33.10%Upside | Reiterated | 10/13/26 | ||
| Gavin Clark-Gartner | Evercore ISI | $65→$70 | buy | 55.28%Upside | Reiterated | 10/13/26 | ||
| Martin Fan | Wedbush | $70 | buy | 55.28%Upside | Reiterated | 10/13/26 | ||
| Yatin Suneja | Guggenheim | $100 | buy | 121.83%Upside | Reiterated | 10/12/26 | ||
| Anupam Rama | J.P. Morgan | ― | buy | ― | Reiterated | 10/12/26 | ||
| Emily Bodnar | H.C. Wainwright | $57 | buy | 26.44%Upside | Reiterated | 09/03/26 | ||
| Michael Yee | UBS | $65 | buy | 44.19%Upside | Assigned | 08/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yasmeen Rahimi | 10/20/26 | $95 | buy | 110.74%Upside | Reiterated | Piper Sandler | ||
| David Risinger | 10/19/26 | $70→$90 | buy | 99.65%Upside | Reiterated | Leerink Partners | ||
| Derek Archila | 10/13/26 | $62→$70 | buy | 55.28%Upside | Reiterated | Wells Fargo | ||
| Etzer Darout | 10/13/26 | $65 | buy | 44.19%Upside | Reiterated | Barclays | ||
| Edward Nash | 10/13/26 | $50→$60 | buy | 33.10%Upside | Reiterated | Canaccord Genuity | ||
| Gavin Clark-Gartner | 10/13/26 | $65→$70 | buy | 55.28%Upside | Reiterated | Evercore ISI | ||
| Martin Fan | 10/13/26 | $70 | buy | 55.28%Upside | Reiterated | Wedbush | ||
| Yatin Suneja | 10/12/26 | $100 | buy | 121.83%Upside | Reiterated | Guggenheim | ||
| Anupam Rama | 10/12/26 | ― | buy | ― | Reiterated | J.P. Morgan | ||
| Emily Bodnar | 09/03/26 | $57 | buy | 26.44%Upside | Reiterated | H.C. Wainwright | ||
| Michael Yee | 08/13/26 | $65 | buy | 44.19%Upside | Assigned | UBS |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering First Tracks Biotherapeutics Inc
3 Months
Success Rate5/5 ratings generated profit
100%
Average Return
+60.76%
Copying Martin Fan's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +60.76% per trade.
1 Year
Success Rate5/5 ratings generated profit
100%
Average Return
+70.18%
Copying Martin Fan's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +70.18% per trade.
2 Years
Success Rate5/5 ratings generated profit
100%
Average Return
+70.18%
Copying Martin Fan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.18% per trade.
TRAX Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 10 | 6 | 4 | 7 | 19 |
| Buy | 1 | 10 | 15 | 17 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 11 | 16 | 19 | 24 | 27 |
In the current month, TRAX has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRAX average Analyst price target in the past 3 months is 74.20.
TRAX Financial Forecast
TRAX Stock Forecast FAQ
What is TRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, First Tracks Biotherapeutics Inc’s 12-month average price target is $74.20.
What is TRAX’s upside potential, based on the analysts’ average price target?
First Tracks Biotherapeutics Inc has 64.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TRAX a Buy, Sell or Hold?
First Tracks Biotherapeutics Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is First Tracks Biotherapeutics Inc’s price target?
The average price target for First Tracks Biotherapeutics Inc is $74.20. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $100.00, the lowest forecast is $57.00. The average price target represents a 64.60% increase from the current price of $45.08.
What do analysts say about First Tracks Biotherapeutics Inc?
First Tracks Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of TRAX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
